Upload Avatar (500 x 500)
Zhen Cai
Medical
Zhejiang University
Zhejiang
Language: Chinese, German, English
Risk Stratification
Multiple Myeloma
Clinical Application
Minimal Residual Disease
Efficacy Evaluation
Prognosis Evaluation
E3 Ligase
Chemotherapy Resistance
Immune Microenvironment
Dna Damage
Areas of Focus
- Establishment and clinical application of new treatment models for multiple myeloma based on risk stratification
- Clinical research on the role of minimal residual disease in the efficacy and prognosis evaluation of multiple myeloma
- Research on the role and mechanism of E3 ligase in the progression of multiple myeloma and chemotherapy resistance to proteasome inhibitors
- Role of the unique immune microenvironment of multiple myeloma in disease occurrence, development, and drug resistance
- Role of myeloma-associated macrophages in inducing DNA damage/repair dysfunction in myeloma cells
Work Experience
- 1984 - Present - Zhejiang University - Clinical diagnosis, teaching, and basic research in hematologic malignancies
- Current - Deputy Director of Bone Marrow Transplantation Center, Director of Multiple Myeloma Treatment Center, Director of Hematology Department at Chengzhan Campus
Academic Background & Achievements
- 1992, 1999, 2004, 2008 - Senior Visiting Scholar: University of Lübeck, Humboldt University, University of Tübingen, M.D. Anderson Cancer Center
- 2016 - Appointed as Second-level Professor at Zhejiang University
- 2014 - Appointed as Qiushi Distinguished Physician at Zhejiang University
- Zhejiang Province '151' High-level Innovative Talent in Health
Awards
- First Prize of Provincial Science and Technology Progress Award: Project Leader
- Second Prize of Provincial Science and Technology Progress Award: Project Leader (2 times)
